ライフサイエンスコーパス: allotransplantation

1 te allografts (VCAs; a.k.a. composite tissue allotransplantation).

2 the potential of the BM as a site for islet allotransplantation.

3 lementation of paediatric vascular composite allotransplantation.

4 timulatory pathway to a murine model of limb allotransplantation.

5 aft-versus-host disease and recurrence after allotransplantation.

6 s on the inflammatory processes triggered by allotransplantation.

7 ising combination for clinical evaluation in allotransplantation.

8 ns for the immunotherapy of autoimmunity and allotransplantation.

9 ay be equally applicable to composite-tissue allotransplantation.

10 d to the development of OAD following airway allotransplantation.

11 on plays a role in the poor success of islet allotransplantation.

12 an primate models of autoimmune diseases and allotransplantation.

13 erivative (RAD), in cynomolgus monkey kidney allotransplantation.

14 solution to the shortage of donor organs for allotransplantation.

15 in a rat hindlimb model of composite tissue allotransplantation.

16 mune-mediated diseases and for outcome after allotransplantation.

17 zation, prior LVAD support, or prior cardiac allotransplantation.

18 l after anti-CD25 induction therapy in islet allotransplantation.

19 in patients (n = 29) who had undergone lung allotransplantation.

20 ne reactivity, when placed in the context of allotransplantation.

21 a promising agent for clinical use in human allotransplantation.

22 le additional risk involved with parathyroid allotransplantation.

23 dness and is a major complication of corneal allotransplantation.

24 most common donor-associated infection after allotransplantation.

25 t survival in the murine model of orthotopic allotransplantation.

26 ic those arising during MHC mismatched human allotransplantation.

27 ransplantation as a practical alternative to allotransplantation.

28 d the risk/benefit balance in bilateral hand allotransplantation.

29 rapy might improve graft survival in cardiac allotransplantation.

30 etic with streptozotocin and underwent islet allotransplantation.

31 to play a significantly greater role than in allotransplantation.

32 confirmed acceptance of PSCs in MHC-matched allotransplantation.

33 tment of rejection in vascularized composite allotransplantation.

34 duction, immunosuppressive therapy, or islet allotransplantation.

35 play a significant role in composite tissue allotransplantation.

36 pproximate the antibody binding occurring in allotransplantation.

37 to address the shortage of human organs for allotransplantation.

38 m deceased individuals continues to restrict allotransplantation.

39 ection after ABO-compatible HLA-incompatible allotransplantation.

40 an outbred non-human primate model of renal allotransplantation.

41 ascular arterial thrombosis in murine aortic allotransplantation.

42 ngle surgical procedure using composite face allotransplantation.

43 tion under stress conditions such as cardiac allotransplantation.

44 de as well as for the graft to survive after allotransplantation.

45 nimum theoretical standard to work toward in allotransplantation.

46 lymphoid tissues as early as 3 h post-islet allotransplantation.

47 ly being investigated in a clinical trial of allotransplantation.

48 ffering new perspectives in composite tissue allotransplantation.

49 in vivo, in models of alloimmune priming and allotransplantation.

50 body formation during the early period after allotransplantation.

51 framework for approaching the endothelium in allotransplantation.

52 on the restoration of facial deformities by allotransplantation.

53 nsplanted along with islets during auto- and allotransplantations.

54 The first human facial allotransplantation, a 38-year-old woman, was performed

55 ational Society on Hand and Composite Tissue Allotransplantation, a section of The Transplantation So

56 unosuppression in mice 30 days before aortic allotransplantation across C57Bl/ 10J (H2b)-->C3H (H2k)

57 The authors performed 30 hind-limb allotransplantations across the MHC barrier between Brow

58 010 over both CyA and SAHA, in the models of allotransplantation adopted.

59 the first report suggestive of CR in a face allotransplantation after immunosuppression minimization

60 er a pig xenograft would preclude subsequent allotransplantation, although the data available suggest

61 at reducing inappropriate immune reaction in allotransplantation and autoimmune diseases.

62 d CD86 can elicit host immune suppression in allotransplantation and autoimmunity.

63 is study, we extended our regimen to cardiac allotransplantation and compared the immunological respo

64 ejection and could potentially be applied to allotransplantation and prevention of the autoimmune rec

65 ndent cellular cytotoxicity, to human AMR in allotransplantation and xenotransplantation and illustra

66 ght reduce subsequent acute rejection, after allotransplantation, and coronary allograft vasculopathy

67 (MHC) are the primary barrier to successful allotransplantation, and here we describe class I MHC mo

68 recipients of successful intrahepatic islet allotransplantation, and in matched control subjects.

69 assist device (LVAD) support, prior cardiac allotransplantation, and pulmonary hypertension, are und

70 njury as manifested in ischemia-reperfusion, allotransplantation, and various vascular diseases.

71 We tested PG27 in rat cardiac and renal allotransplantation, and we examined the immunosuppressi

72 evidence that autoimmune responses following allotransplantation are damaging and cause accelerated g

73 The complications in composite tissue allotransplantation are similar to those usually reporte

74 , support the continued application of islet allotransplantation as a treatment modality for type 1 d

75 The extent to which renal allotransplantation - as compared with long-term dialysi

76 (1) OAD occurs not only after tracheal allotransplantation but also after xenotransplantation.

77 have use as an adjunctive agent for clinical allotransplantation, but using the dosing regimens we us

78 Before a human clinical trial of hepatocyte allotransplantation can be attempted, preliminary experi

79 ), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P

80 Composite tissue allotransplantation (CTA) has been recently introduced a

81 Numerous experiments in composite tissue allotransplantation (CTA) have identified skin as the mo

82 Composite tissue allotransplantation (CTA) is a recently introduced optio

83 Composite tissue allotransplantation (CTA) is a recently introduced optio

84 The science of composite tissue allotransplantation (CTA) is rooted in progressive think

85 Composite tissue allotransplantation (CTA) represents a surgical technolo

86 deal model to study various composite tissue allotransplantation (CTA)-related problems, we designed

87 After allotransplantation, cytomegalovirus (CMV) may be transm

88 Allotransplantations (DA-->BN) were performed (n=8), wit

89 ALB/c and NOD mice and that successful islet allotransplantation depends on the degree of hyperglycem

90 After single lung allotransplantation, dogs were maintained on standard tr

91 n = 4) who underwent facial composite tissue allotransplantation (FCTA) at our center between April 2

92 sion is being developed as a bridge to liver allotransplantation for patients with fulminant hepatic

93 mples from patients awaiting cadaveric renal allotransplantation for reactivity against: 1) human; 2)

94 Until recently, islet allotransplantation for type 1 diabetic patients has bee

95 Seven outbred baboons underwent renal allotransplantation from major histocompatibility comple

96 tes after heterotopic partial facial segment allotransplantation from major histocompatibility comple

97 bred juvenile rhesus monkeys underwent renal allotransplantation from MHC-disparate donors.

98 In multivariate analyses, allotransplantation had higher TRM and lower disease rec

99 Although heterologous vascular composite allotransplantation has become a burgeoning treatment op

100 Vascularized composite allotransplantation has become established as a clinical

101 Hepatocyte allotransplantation has been performed successfully in s

102 During the last decade, face allotransplantation has been shown to be a revolutionary

103 pite technical feasibility, composite tissue allotransplantation has not been applied clinically beca

104 nic rejection (CR) in vascularized composite allotransplantation has not been included in the Banff c

105 The success of allotransplantation has paradoxically led to a shortage

106 in the supply of human organs available for allotransplantation has turned attention toward the use

107 menon repeats itself after second same donor allotransplantation, hoping to determine whether accepta

108 he widespread clinical use of reconstructive allotransplantation if protocols to achieve this could b

109 allotransplantation was inaugurated by hand allotransplantation in 1998, giving rise to many controv

110 Composite tissue allotransplantation in a 30-year-old male was used as a

111 lts in clinical trials, in contrast to islet allotransplantation in animal models, which have demonst

112 LA-4 pathway, and belatacept (n=5) in kidney allotransplantation in baboons.

113 in contrast to clinical experience with AB-I allotransplantation in infants, who cease producing only

114 Aortic allotransplantation in mice has been well established as

115 TG) for effects on anti-mATG Abs and cardiac allotransplantation in mice.

116 and LFA-1 in the challenging model of islet allotransplantation in NOD mice.

117 good tolerability in a preclinical model of allotransplantation in nonhuman primates and thus has in

118 monoclonal antibody (hu5C8) allows for renal allotransplantation in outbred, MHC-mismatched rhesus mo

119 doses of corticosteroid hormones after renal allotransplantation in the era of cyclosporine and tacro

120 emonstrate that immune tolerance after organ allotransplantation in the rat is associated with a repr

121 poglycemia and 2) whether intrahepatic islet allotransplantation in type I diabetic patients and cons

122 Unlike human allotransplantation, in which the important antigenic di

123 st that activation of donor T cells after SB allotransplantation induces production of a Th1-like pro

124 Allotransplantation into immunosuppressed individuals re

125 Whole liver allotransplantation is limited by a shortage of human do

126 The decreased recurrence after allotransplantation is offset by increased TRM.

127 between bone marrow transplantation and limb allotransplantation is required, making such protocols i

128 ined HLA-matched donor bone marrow and renal allotransplantation is the first example of an intention

129 cold ischemia (CI) in vascularized composite allotransplantation is unknown.

130 Pregnancy after allotransplantations is becoming a more common occurrenc

131 on of graft survival after intraportal islet allotransplantation (ITx) in rats: 7.2 days in the contr

132 human cytomegalovirus (HCMV) infection after allotransplantation led us to evaluate whether baboon cy

133 yeloablative preconditioning and barriers to allotransplantation limit this therapy to children with

134 Composite tissue allotransplantation may have different immunosuppressive

135 natives to the current technology of cardiac allotransplantation may include xenotransplantation and/

136 plants using nonmyeloablative regimens (mini-allotransplantations) may hold promise for more widely e

137 mobilized and collected T cells, which after allotransplantation, might positively affect the inciden

138 t arteriosclerosis in a rat orthotopic aorta allotransplantation model (Brown Norway to Lewis).

139 minates this delay period in a rat hind limb allotransplantation model by performing mixed allogeneic

140 a non-human primate facial composite tissue allotransplantation model to investigate strategies to a

141 "Third-party" controls and a skin allotransplantation model were used to confirm DSAs' spe

142 on with cyclosporine (CsA) in a rat hindlimb allotransplantation model with a major antigenic mismatc

143 In a heterotopic cardiac allotransplantation model, CD73 deficiency in either don

144 leflunomide (5, 15, and 35 mg/kg/day) in the allotransplantation model.

145 to prevent graft rejection in a mouse heart allotransplantation model; the highest dose tested (1.5

146 y function after single-donor clinical islet allotransplantation (n = 7).

147 p 1 Cynomolgus monkeys (n=6) underwent TIR + allotransplantation of hematopoietic cells and a kidney

148 Numerous studies have reported successful allotransplantation of hepatocytes.

149 Furthermore, allotransplantation of HPCs from APAP+ISO-treated mice t

150 Allotransplantation of MSCs may alleviate some of these

151 ble immune tolerance supporting vascularized allotransplantation offers the possibility of extending

152 As a theoretical alternative to allotransplantation, patient-derived bioartificial myoca

153 d in 64 liver transplant patients, 59 kidney allotransplantation patients and six lung transplant pat

154 The study included 5 cases of bilateral hand allotransplantation performed in a single center, with a

155 ecurrence rates were 21%, 43%, and 58% after allotransplantation, purged autotransplantation, and unp

156 ory receptors on T cells and modification of allotransplantation regimens have all produced new tumor

157 he role of CD4+ and CD8+ cells in initiating allotransplantation rejection.

158 BACKGROUND Following allotransplantation, renal ischemia-reperfusion (I/R) in

159 In allotransplantation, several unique factors influence th

160 Ischemia times in vascularized composite allotransplantation should be kept as short as possible

161 In rodents, spleen allotransplantation (SpTx) induces tolerance.

162 together, our results suggest that following allotransplantation, T cell responses to donor antigens

163 In July, 2015, our vascularised composite allotransplantation team did the first bilateral hand an

164 trategy for tolerance induction in laryngeal allotransplantation that permits escape from chronic imm

165 n this study, using a murine model of aortic allotransplantation, the role of blockade of signaling t

166 In allotransplantation, the successful transplantation of h

167 After allotransplantation, there was up-regulation of all 11 c

168 e our initial experience with abdominal wall allotransplantation to facilitate abdominal closure.

169 y of conventional BMT and expands the use of allotransplantation to non-HLA-matched donors.

170 38 months and 47 +/- 40 months after cardiac allotransplantation (TX).

171 r immunomodulation in vascularized composite allotransplantation (VCA) have gained importance due to

172 imate model of facial vascularized composite allotransplantation (VCA) to study the association of Tr

173 y induce tolerance in vascularized composite allotransplantation (VCA) with chimerism through bone ma

174 clinical expansion of vascularized composite allotransplantation (VCA).

175 ng process for vascularized composite tissue allotransplantation (VCTA) closely follows the standard

176 The clinic era of composite tissue allotransplantation was inaugurated by hand allotranspla

177 Life-supporting allotransplantation was performed in bilaterally nephrec

178 The allotransplantation was performed simultaneously on 2 ad

179 Left lung allotransplantation was performed, and recipients were m

180 Allotransplantation was then tested.

181 Using a well-characterized model of corneal allotransplantation, we demonstrate in this study that T

182 th research on penile vascularized composite allotransplantation will require the articulation of gui

183 These patients might be candidates for allotransplantation with (SLE)-resistant major histocomp

184 Profound T-cell depletion before allotransplantation with gradual posttransplant T-cell r

185 In response to airway allotransplantation with grafts expressing the OVA trans

186 in preventing acute rejection in adult liver allotransplantation with less renal toxicity and less us

187 In conclusion, allotransplantation with RIC or NMAC induces long-term p

188 aluated in19 monkeys that underwent auto- or allotransplantation, with or without subtherapeutic immu